The expression of the truncated isoform of somatostatin receptor subtype 5 associates with aggressiveness in medullary thyroid carcinoma cells

详细信息    查看全文

• 作者：Daniela Molè ; Erica Gentilin ; Alejandro Ibañez-Costa ; Teresa Gagliano…
• 关键词：sst5TMD4 ; Medullary thyroid carcinoma ; TT cells ; sst5
• 刊名：Endocrine
• 出版年：2015
• 出版时间：November 2015
• 年：2015
• 卷：50
• 期：2
• 页码：442-452
• 全文大小：844 KB
• 参考文献：1.M.P. Pusztaszeri, M. Bongiovanni, W.C. Faquin, Update on the cytologic and molecular features of medullary thyroid carcinoma. Adv. Anat. Pathol. 21, 26–35 (2014)CrossRef PubMed
  2.S.A. Wells Jr, F. Pacini, B.G. Robinson, M. Santoro, Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update. J. Clin. Endocrinol. Metab. 98, 3149–3164 (2013)CrossRef PubMed
  3.C. Schreiber, K. Vormbrock, U. Ziebold, Genes involved in the metastatic cascade of medullary thyroid tumours. Methods Mol. Biol. 878, 217–228 (2012)CrossRef PubMed
  4.L. Santarpia, G.A. Calin, L. Adam, L. Ye, A. Fusco, S. Giunti, C. Thaller, L. Paladini, X. Zhang, C. Jimenez, F. Trimarchi, A.K. El-Naggar, R.F. Gagel, A miRNA signature associated with human metastatic medullary thyroid carcinoma. Endocr. Relat. Cancer 20, 809–823 (2013)CrossRef PubMed
  5.M. Ruscica, M. Arvigo, L. Steffani, D. Ferone, P. Magni, Somatostatin, somatostatin analogs and somatostatin receptor dynamics in the biology of cancer progression. Curr. Mol. Med. 13, 555–571 (2013)CrossRef PubMed
  6.M.C. Zatelli, D. Piccin, F. Tagliati, A. Bottoni, A. Luchin, C. Vignali, A. Margutti, M. Bondanelli, G.C. Pansini, M.R. Pelizzo, M.D. Culler, E.C. degli Uberti, Selective activation of somatostatin receptor subtypes differentially modulates secretion and viability in human medullary thyroid carcinoma primary cultures: potential clinical perspectives. J. Clin. Endocrinol. Metab. 91, 2218–2224 (2006)CrossRef PubMed
  7.J. Strosberg, L. Kvols, Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors. World J. Gastroenterol. 16, 2963–2970 (2010)PubMedCentral CrossRef PubMed
  8.A. Rinke, H.H. Müller, C. Schade-Brittinger, K.J. Klose, P. Barth, M. Wied, C. Mayer, B. Aminossadati, U.F. Pape, M. Bläker, J. Harder, C. Arnold, T. Gress, R. Arnold, PROMID Study Group, Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J. Clin. Oncol. 27, 4656–4663 (2009)CrossRef PubMed
  9.M.E. Caplin, M. Pavel, J.B. Ćwikła, A.T. Phan, M. Raderer, E. Sedláčková, G. Cadiot, E.M. Wolin, J. Capdevila, L. Wall, G. Rindi, A. Langley, S. Martinez, J. Blumberg, P. Ruszniewski, CLARINET Investigators, Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N. Engl. J. Med. 371, 224–233 (2014)CrossRef PubMed
  10.E. Mato, X. Matías-Guiu, A. Chico, S.M. Webb, R. Cabezas, L. Berná, A. De Leiva, Somatostatin and somatostatin receptor subtype gene expression in medullary thyroid carcinoma. J. Clin. Endocrinol. Metab. 83, 2417–2420 (1998)PubMed
  11.G. Vitale, M. Caraglia, A. Ciccarelli, G. Lupoli, A. Abbruzzese, P. Tagliaferri, Current approaches and perspectives in the therapy of medullary thyroid carcinoma. Cancer 91, 1797–1808 (2001)CrossRef PubMed
  12.M.C. Zatelli, F. Tagliati, J.E. Taylor, R. Rossi, M.D. Culler, E.C. degli Uberti, Somatostatin receptor subtypes 2 and 5 differentially affect proliferation in vitro of the human medullary thyroid carcinoma cell line TT. J. Clin. Endocrinol. Metab. 86, 2161–2169 (2001)PubMed
  13.M. Durán-Prado, M.D. Gahete, A.J. Martínez-Fuentes, R.M. Luque, A. Quintero, S.M. Webb, P. Benito-López, A. Leal, S. Schulz, F. Gracia-Navarro, M.M. Malagón, J.P. Castaño, Identification and characterization of two novel truncated but functional isoforms of the somatostatin receptor subtype 5 differentially present in pituitary tumors. J. Clin. Endocrinol. Metab. 94, 2634–2643 (2009)CrossRef PubMed
  14.M. Durán-Prado, A. Saveanu, R.M. Luque, M.D. Gahete, F. Gracia-Navarro, P. Jaquet, H. Dufour, M.M. Malagón, M.D. Culler, A. Barlier, J.P. Castaño, A potential inhibitory role for the new truncated variant of somatostatin receptor 5, sst5TMD4, in pituitary adenomas poorly responsive to somatostatin analogs. J. Clin. Endocrinol. Metab. 95, 2497–2502 (2010)CrossRef PubMed
  15.M. Durán-Prado, M.D. Gahete, M. Hergueta-Redondo, A.J. Martínez-Fuentes, J. Córdoba-Chacón, J. Palacios, F. Gracia-Navarro, G. Moreno-Bueno, M.M. Malagón, R.M. Luque, J.P. Castaño, The new truncated somatostatin receptor variant sst5TMD4 is associated to poor prognosis in breast cancer and increases malignancy in MCF-7 cells. Oncogene 31, 2049–2061 (2012)CrossRef PubMed
  16.M. Puig-Domingo, R.M. Luque, J.L. Reverter, L.M. López-Sánchez, M.D. Gahete, M.D. Culler, G. Díaz-Soto, F. Lomeña, M. Squarcia, J.L. Mate, M. Mora, L. Fernández-Cruz, O. Vidal, A. Alastrué, J. Balibrea, I. Halperin, D. Mauricio, J.P. Castaño, The truncated isoform of somatostatin receptor5 (sst5TMD4) is associated with poorly differentiated thyroid cancer. PLoS One 9, e85527 (2014)PubMedCentral CrossRef PubMed
  17.M. Durán-Prado, M.D. Gahete, E. Delgado-Niebla, A.J. Martínez-Fuentes, R. Vázquez-Martínez, S. García-Navarro, F. Gracia-Navarro, M.M. Malagon, R.M. Luque, J.P. Castaño, Truncated variants of pig somatostatin receptor subtype 5 (sst5) act as dominant-negative modulators for sst2-mediated signaling. Am. J. Physiol. Endocrinol. Metab. 303, E1325–E1334 (2012)CrossRef PubMed
  18.L.H. Sobin, in TNM classification of malignant tumours, ed. by L.H. Sobin, M.K. Gospodarowicz, C. Wittekind (Wiley, Hoboken, 2009), p. 58
  19.M. Andreoli, A new cell line for study of human medullary carcinoma, in Advances in thyroid neoplasia, ed. by S.S. Leong, J.S. Horoszewicz, K. Shimaoka (Field Educational, Rome, 1981), pp. 95–108
  20.L.D. Cooley, F.F. Elder, A. Knuth, R.F. Gagel, Cytogenetic characterization of three human and three rat medullary thyroid carcinoma cell lines. Cancer Genet. Cytogenet. 80, 138–149 (1995)CrossRef PubMed
  21.M.C. Zatelli, F. Tagliati, D. Piccin, J.E. Taylor, M.D. Culler, M. Bondanelli, E.C. degli Uberti, Somatostatin receptor subtype 1 selective activation reduces cell growth and calcitonin secretion in a human medullary thyroid carcinoma cell line. Biochem. Biophys. Res. Commun. 297, 828–834 (2002)CrossRef PubMed
  22.M.C. Zatelli, F. Tagliati, J.E. Taylor, D. Piccin, M.D. Culler, E.C. degli Uberti, Somatostatin, but not somatostatin receptor subtypes 2 and 5 selective agonists, inhibits calcitonin secretion and gene expression in the human medullary thyroid carcinoma cell line, TT. Horm. Metab. Res. 34, 229–233 (2002)CrossRef PubMed
  23.M.C. Zatelli, M. Minoia, C. Martini, F. Tagliati, M.R. Ambrosio, M. Schiavon, M. Buratto, F. Calabrese, E. Gentilin, G. Cavallesco, L. Berdondini, F. Rea, E.C. degli Uberti, Everolimus as a new potential antiproliferative agent in aggressive human bronchial carcinoids. Endocr. Relat. Cancer 17, 719–729 (2010)CrossRef PubMed
  24.M.C. Zatelli, R. Rossi, E.C. degli Uberti, Androgen influences transforming growth factor-β1 gene expression in human adrenocortical cells. J. Clin. Endocrinol. Metab. 85, 847–852 (2000)PubMed
  25.G.F. Taboada, R.M. Luque, W. Bastos, R.F. Guimaraes, J.B. Marcondes, L.M. Chimelli, R. Fontes, P.J. Mata, P.N. Filho, D.P. Carvalho, R.D. Kineman, M.R. Gadelha, Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas. Eur. J. Endocrinol. 156, 65–74 (2007)CrossRef PubMed
  26.A. Hamm, N. Krott, I. Breibach, R. Blindt, A.K. Bosserhoff, Efficient transfection method for primary cells. Tissue Eng. 8, 235–245 (2002)CrossRef PubMed
  27.D. Molè, E. Gentilin, T. Gagliano, F. Tagliati, M. Bondanelli, M.R. Pelizzo, M. Rossi, C. Filieri, G. Pansini, E.C. degli Uberti, M.C. Zatelli, Protein kinase C: a putative new target for the control of human medullary thyroid carcinoma cell proliferation in vitro. Endocrinology 153, 2088–2098 (2012)CrossRef PubMed
  28.M.C. Zatelli, D. Molè, F. Tagliati, M. Minoia, M.R. Ambrosio, E. degli Uberti, Cyclo-oxygenase 2 modulates chemoresistance in breast cancer cells involving NF-kappaB. Cell Oncol. 31, 457–465 (2009)PubMed
  29.E. Gentilin, F. Tagliati, C. Filieri, D. Molè, M. Minoia, M.R. Ambrosio, E.C. degli Uberti, M.C. Zatelli, miR-26a plays an important role in cell cycle regulation in ACTH-secreting pituitary adenomas by modulating protein kinase Cδ. Endocrinology 154, 1690–1700 (2013)PubMedCentral CrossRef PubMed
  30.T. Gagliano, C. Filieri, M. Minoia, M. Buratto, F. Tagliati, M.R. Ambrosio, M. Lapparelli, M. Zoli, G. Frank, E. degli Uberti, M.C. Zatelli, Cabergoline reduces cell viability in non functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion. Pituitary 16, 91–100 (2013)CrossRef PubMed
  31.A. Singh, J. Settleman, EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29, 4741–4751 (2010)PubMedCentral CrossRef PubMed
  32.J. Yang, R.A. Weinberg, Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev. Cell 14, 818–829 (2008)CrossRef PubMed
  33.L. Larue, A. Bellacosa, Epithelial–mesenchymal transition in development and cancer: role of phosphatidylinositol 3′ kinase/AKT pathways. Oncogene 24, 7443–7454 (2005)CrossRef PubMed
  34.J. Córdoba-Chacón, M.D. Gahete, M. Durán-Prado, R.M. Luque, J.P. Castaño, Truncated somatostatin receptors as new players in somatostatin-cortistatin pathophysiology. Ann. N. Y. Acad. Sci. 1220, 6–15 (2011)CrossRef PubMed
  35.M.C. Zatelli, D. Piccin, A. Bottoni, M.R. Ambrosio, A. Margutti, R. Padovani, M. Scanarini, J.E. Taylor, M.D. Culler, L. Cavazzini, E.C. degli Uberti, Evidence for differential effects of selective somatostatin receptor subtype agonists on alpha-subunit and chromogranin a secretion and on cell viability in human nonfunctioning pituitary adenomas in vitro. J. Clin. Endocrinol. Metab. 89, 5181–5188 (2004)CrossRef PubMed
  36.C. Rodríguez-Antona, I. Muñoz-Repeto, L. Inglada-Pérez, A.A. de Cubas, V. Mancikova, M. Cañamero, A. Maliszewska, A. Gómez, R. Letón, L.J. Leandro-García, I. Comino-Méndez, L. Sanchez, C. Alvarez-Escolá, J. Aller, A. Cascón, M. Robledo, Influence of RET mutations on the expression of tyrosine kinases in medullary thyroid carcinoma. Endocr. Relat. Cancer 20, 611–619 (2013)CrossRef PubMed
  37.J.J. Christiansen, A.K. Rajasekaran, Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res. 66, 8319–8326 (2006)CrossRef PubMed
  38.A. Satelli, S. Li, Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell. Mol. Life Sci. 68, 3033–3046 (2011)PubMedCentral CrossRef PubMed
  39.V. Easwaran, S.H. Lee, L. Inge, L. Guo, C. Goldbeck, E. Garrett, M. Wiesmann, P.D. Garcia, J.H. Fuller, V. Chan, F. Randazzo, R. Gundel, R.S. Warren, J. Escobedo, S.L. Aukerman, R.N. Taylor, W.J. Fantl, beta-Catenin regulates vascular endothelial growth factor expression in colon cancer. Cancer Res. 63, 3145–3153 (2003)PubMed
  
• 作者单位：Daniela Molè (1)
  Erica Gentilin (1) (2)
  Alejandro Ibañez-Costa (3)
  Teresa Gagliano (1)
  Manuel D. Gahete (3)
  Federico Tagliati (1)
  Roberta Rossi (1)
  Maria Rosa Pelizzo (4)
  Giancarlo Pansini (5)
  Raúl M. Luque (3)
  Justo P. Castaño (3)
  Ettore degli Uberti (1) (2)
  Maria Chiara Zatelli (1) (2)
  
  1. Section of Endocrinology and Internal Medicine, Department of Medical Sciences, University of Ferrara, Via Savonarola 9, 44100, Ferrara, Italy
  2. Laboratorio in rete del Tecnopolo “Tecnologie delle terapie avanzate” (LTTA), University of Ferrara, Ferrara, Italy
  3. Department of Cell Biology, Physiology and Immunology, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Hospital Universitario Reina Sofia, and CIBER Fisiopatología de la Obesidad y Nutrición, Córdoba, University of Cordoba, 14014, Córdoba, Spain
  4. Department of Surgical, Oncological and Gastroenterological Sciences, University of Padova, Via Giustiniani 2, Padua, Italy
  5. Depatment of Surgery, University of Ferrara, Via Savonarola 9, 44100, Ferrara, Italy
  
• 刊物主题：Endocrinology; Diabetes; Internal Medicine; Science, general;
• 出版者：Springer US
• ISSN：1559-0100

文摘

The truncated somatostatin receptor variant sst5TMD4 associates with increased invasiveness and aggressiveness in breast cancer. We previously found that sst5 activation may counteract sst2 selective agonist effects in a medullary thyroid carcinoma (MTC) cell line, the TT cells, and that sst5TMD4 is overexpressed in poorly differentiated thyroid cancers. The purpose of this study is to evaluate sst5TMD4 expression in a series of human MTC and to explore the functional role of sst5TMD4 in TT cells. We evaluated sst5TMD4 and sst5 expression in 36 MTC samples. Moreover, we investigated the role of sst5TMD4 in TT cells evaluating cell number, DNA synthesis, free cytosolic calcium concentration ([Ca2+]_i), calcitonin and vascular endothelial growth factor levels, cell morphology, protein expression, and invasion. We found that in MTC the balance between sst5TMD4 and sst5 expression influences disease stage. sst5TMD4 overexpression in TT cells confers a greater growth capacity, blocks sst2 agonist-induced antiproliferative effects, modifies the cell phenotype, decreases E-cadherin and phosphorylated β-catenin levels, increases vimentin, total β-catenin and phosphorylated GSK3B levels (in keeping with the development of epithelial to mesenchymal transition), and confers a greater invasion capacity. This is the first evidence indicating that sst5TMD4 is expressed in human MTC cells, where it associates with more aggressive behavior, suggesting that sst5TMD4 might play a functionally relevant role.